Jaime Espín Balbino
Jaime Espín Balbino
Escuela Andaluza de Salud Pública
Dirección de correo verificada de easp.es
Citado por
Citado por
Analysis of differences and commonalities in pricing and reimbursement systems in Europe
J Espin, J Rovira
Brussels: DG Enterprise and Industry of the European Commission 100, 2007
WHO guideline on country pharmaceutical pricing policies
World Health Organization
World Health Organization, 2015
Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis
E Molina-Montes, B Pérez-Nevot, M Pollán, E Sánchez-Cantalejo, J Espín, ...
The Breast 23 (6), 721-742, 2014
Working paper 1: External price referencing–review series on pharmaceutical pricing policies and interventions
J Espin, J Rovira, AO de Labry
Geneva: World Health Organization and Health Action International, 2011
Experiences and impact of European risk-sharing schemes focusing on oncology medicines
J Espín, J Rovira, L García
Brussels: Commissioned by the European Commission, Directorate-General …, 2011
The impact of biosimilars’ entry in the EU market
J Rovira, J Espín, L García, A Olry de Labry
Andalusian Sch Pub Health 30, 1-83, 2011
Pharmaceutical pricing and reimbursement information (PPRI)–new PPRI analysis including Spain
S Vogler, J Espin, C Habl
Pharmaceuticals Policy and Law 11 (3), 213-234, 2009
Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis
E Molina-Montes, M Requena, E Sánchez-Cantalejo, MF Fernández, ...
Gynecologic oncology 136 (1), 158-171, 2015
Short-and long-term effects of value-based pricing vs. external price referencing
P Kanavos, E Nicod, J Espin, S Van Den Aardweg
Eminet. LSE, 2010
How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe
J Espín, J Rovira, A Calleja, N Azzopardi-Muscat, E Richardson, W Palm, ...
Policy brief 21, 2016
Personalised medicine as a challenge for public pricing and reimbursement authorities–A survey among 27 European countries on the example of trastuzumab
C Leopold, S Vogler, C Habl, AK Mantel-Teeuwisse, J Espin
Health Policy 113 (3), 313-322, 2013
Pandemic influenza control in Europe and the constraints resulting from incoherent public health laws
R Martin, A Conseil, A Longstaff, J Kodo, J Siegert, AM Duguet, ...
BMC Public Health 10 (1), 532, 2010
Esquemas innovadores de mejora del acceso al mercado de nuevas tecnologías: los acuerdos de riesgo compartido
J Espín, J Oliva, JM Rodríguez-Barrios
Gaceta Sanitaria 24, 491-497, 2010
Medicine Prices in Latin American Countries
JE Balbino, JR Forns, CV González
Medicine Price Surveys, Analyses and Comparisons, 61-83, 2019
Biosimilars in the European market
J Rovira, L Lindner, E Gimenez, J Espín, AO de Labry, L García
GaBI J 2 (1), 30-5, 2013
HTA and decision-making processes in Central, Eastern and South Eastern Europe: results from a survey
L García-Mochón, JE Balbino, AO de Labry Lima, AC Martinez, EM Ruiz, ...
Health Policy 123 (2), 182-190, 2019
Cuestiones controvertidas en evaluación económica (I): perspectiva y costes de intervenciones sanitarias
J Oliva, M Brosa, J Espín, M Figueras, M Trapero
Revista Española de Salud Pública 89 (1), 5-14, 2015
Mapping external reference pricing practices for medicines
J Espin, J Rovira, M Ewen, R Laing
Health Action International and the Andalusian School of Public Health, 2014
All you need to know about innovation in healthcare: The 10 best reads
S Ilinca, S Hamer, D Botje, J Espin, RV Mendes, J Mueller, ...
International Journal of healthcare management 5 (4), 193-202, 2012
Projecting pharmaceutical expenditure in EU5 to 2021: adjusting for the impact of discounts and rebates
J Espin, M Schlander, B Godman, P Anderson, J Mestre-Ferrandiz, ...
Applied health economics and health policy 16 (6), 803-817, 2018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20